Overview

Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma

Status:
Completed

Trial end date:
2019-04-01

Target enrollment:
0

Participant gender:
All

Summary

In this study the investigators aim to evaluate diagnostic utility of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma (RCC).

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Johns Hopkins University

Criteria

Inclusion Criteria:

- Clinically diagnosed or histologically proven stage II-IV renal cell carcinoma

- Completed staging evaluation with computed tomography (CT) or magnetic resonance
imaging (MRI) of the chest, abdomen and pelvis ≤90 days prior to study enrollment

Exclusion Criteria:

- History of other malignancy diagnosed within the last 3 years (with the exception of
low risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell
carcinoma or basal cell carcinoma of the skin)

- Administered a radioisotope within 5 physical half-lives prior to study enrollment

- Pregnancy ((as determined in accordance with the policies of the positron emission
tomography (PET) center))

- Intention to enroll in a blinded therapeutic clinical trial following Positron
emission tomography-computed tomography (PET/CT)